% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Szles:300213,
      author       = {Á. Széles and A. Kubik and S. Váncsa and V.
                      Grünwald$^*$ and B. Hadaschik$^*$ and N. Ács and P. Hegyi
                      and P. Nyirády and T. Szarvas$^*$},
      title        = {{P}rognostic and predictive value of pre-treatment
                      blood-based inflammatory biomarkers in patients with
                      urothelial carcinoma treated with immune checkpoint
                      inhibitors: a systematic review and meta-analysis.},
      journal      = {Frontiers in immunology},
      volume       = {16},
      issn         = {1664-3224},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2025-00679},
      pages        = {1554048},
      year         = {2025},
      abstract     = {The therapeutic landscape of locally advanced or metastatic
                      urothelial carcinoma (mUC) is rapidly evolving, and immune
                      checkpoint inhibitors (ICI) have become an integral part of
                      the standard therapy. However, the majority of patients do
                      not benefit from this treatment. Hence, finding prognostic
                      and predictive biomarkers may improve therapeutic
                      decision-making. The aim of this study was to analyze the
                      prognostic and predictive significance of liquid biomarkers
                      (NLR, CRP, PLR, and LDH) in mUC patients treated with ICI.We
                      collected articles from PubMed, Cochrane, and Embase
                      databases with primary outcomes of overall survival (OS),
                      progression-free survival (PFS) and objective response rate
                      (ORR).We compiled data from a total of 6,673 ICI-treated
                      patients with locally advanced or mUC from 31 articles.
                      Pooled univariate analysis demonstrated that high
                      pre-treatment NLR is significantly associated with worse OS
                      (HR: 2.19; $95\%$ CI: 1.80-2.68) and PFS (HR: 1.90; $95\%$
                      CI: 1.57-2.31). Similarly, elevated CRP levels were
                      associated with worse OS (HR: 1.75; $95\%$ CI: 1.37-2.24)
                      and PFS (HR: 1.58; $95\%$ CI: 1.26-1.99).Elevated
                      pre-treatment NLR, CRP, PLR, and LDH are significantly
                      associated with worse OS and PFS in ICI-treated urothelial
                      carcinoma patients, suggesting that they have potential
                      prognostic and predictive value in treatment decisions.In
                      this systematic review and meta-analysis we summarized the
                      existing data on inflammatory laboratory biomarkers and
                      their potential impact on immunotherapy outcomes in
                      urothelial cancers.https://www.crd.york.ac.uk/prospero/,
                      identifier CRD42022291449.},
      subtyp        = {Review Article},
      keywords     = {Humans / Immune Checkpoint Inhibitors: therapeutic use /
                      Biomarkers, Tumor: blood / Prognosis / Urologic Neoplasms:
                      drug therapy / Urologic Neoplasms: mortality / Urologic
                      Neoplasms: immunology / Urologic Neoplasms: diagnosis /
                      Urologic Neoplasms: blood / Carcinoma, Transitional Cell:
                      drug therapy / Carcinoma, Transitional Cell: blood /
                      Carcinoma, Transitional Cell: mortality / Carcinoma,
                      Transitional Cell: immunology / Urinary Bladder Neoplasms:
                      drug therapy / Urinary Bladder Neoplasms: blood / Urinary
                      Bladder Neoplasms: mortality / Urinary Bladder Neoplasms:
                      immunology / Predictive Value of Tests / CRP (Other) / NLR
                      (Other) / PLR (Other) / bladder cancer (Other) / immune
                      checkpoint inhibitor (Other) / urothelial carcinoma (Other)
                      / Immune Checkpoint Inhibitors (NLM Chemicals) / Biomarkers,
                      Tumor (NLM Chemicals)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40165971},
      pmc          = {pmc:PMC11955586},
      doi          = {10.3389/fimmu.2025.1554048},
      url          = {https://inrepo02.dkfz.de/record/300213},
}